This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: Humana Inc. (HUM)
by Benjamin Rains
Humana's near-term bull case and its long-term potential both hinge on some rather large-scale societal trends that are hard to bet against. And HUM stock just hit new highs...
Molina (MOH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.59% and 0.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana
by Zacks Equity Research
Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.
Best Value Stocks to Buy for October 26th
by Zacks Equity Research
CBNK, TKR and HUM made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 26, 2022.
3 Top-Ranked Medical Stocks Lapping the S&P 500
by Derek Lewis
All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are anticipated to have enhanced consumer engagement across all CVS Health businesses in Q3.
What's in the Cards for Illumina (ILMN) in Q3 Earnings?
by Zacks Equity Research
The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.
3 Healthcare Stocks Set to Outshine Q3 Earnings Estimates
by Kaibalya Pravo Dey
Recovering volumes, improved admissions, growing health awareness and wide utilization of technologies in the third quarter are expected to have aided healthcare stocks like Humana (HUM), Teladoc (TDOC) and Pediatrix Medical (MD).
Can Rising Visits Help Teladoc (TDOC) Beat on Earnings in Q3?
by Zacks Equity Research
The third-quarter results of Teladoc (TDOC) are likely to reflect a rise in Access Fees and Visit Fee revenues.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Universal Health (UHS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Universal Health's (UHS) Q3 results are likely to reflect sound segmental performances resulting from a constant pursuit of expansion moves. However, high labor costs might partly offset the results.
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.
Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q4 Earnings
by Zacks Equity Research
Hologic's (HOLX) Molecular Diagnostics sales are likely to have been affected by the significant drop in demand for COVID-19 testing.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.
Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View
by Zacks Equity Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.
Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.